9 Things to Know Before Taking Ashwagandha for Menopause Stress and Cortisol
The number of women who come to this site already taking ashwagandha, but unsure whether it's actually doing anything, is striking. It's one of those supplements that sounds almost too sensible to question — adaptogen, cortisol, stress, menopause — the words just line up so neatly. But 'it makes sense' and 'it works for me at a meaningful dose without interacting with my thyroid medication' are very different conversations, and women deserve to have the second one.
Learn more about Rose →The cortisol connection is real, but more modest than the marketing suggests
Ashwagandha (Withania somnifera) contains withanolides, compounds that appear to modulate the hypothalamic-pituitary-adrenal (HPA) axis — the same stress-response system that gets dysregulated during perimenopause as estrogen declines. Several randomized controlled trials have shown statistically significant reductions in serum cortisol levels, with one well-cited 2012 trial showing roughly a 28% reduction over 60 days in chronically stressed adults. That is a real effect, but it is not the same as eliminating stress, and it does not replace the hormonal stabilization that falling estrogen actually demands.
Most of the clinical trials used specific, standardized root extracts — not generic powder
The studies showing benefits used standardized extracts — typically KSM-66 or Sensoril — with defined withanolide concentrations, usually between 300mg and 600mg daily. Bulk ashwagandha powder, root capsules of unspecified potency, and products listing 'proprietary blends' are not equivalent to the trial preparations, and there is no reliable way to know how they compare. This matters because a woman trying an unstandardized product and feeling nothing may be drawing the wrong conclusion in either direction.
Sleep quality improvements are among the more consistently reported benefits
Multiple trials in stressed adults and older populations have found that ashwagandha supplementation improved self-reported sleep quality, sleep onset latency, and morning alertness — outcomes that are particularly relevant for perimenopausal women whose sleep is already disrupted by night sweats, anxiety, and hormonal fluctuation. A 2020 randomized trial specifically in adults with insomnia found meaningful improvements at 600mg daily of a root extract over eight weeks. The mechanism is thought to involve triethylene glycol, a compound in the leaves and root that may promote non-rapid eye movement sleep.
Thyroid hormone levels can be affected — and this is not a minor footnote
Ashwagandha has been shown in some studies to increase serum T3 and T4 thyroid hormone levels, which is presented as a benefit in thyroid-support marketing but is a genuine safety concern for anyone with hyperthyroidism, Hashimoto's thyroiditis, or who is already on thyroid medication such as levothyroxine. Perimenopausal women have a significantly elevated risk of autoimmune thyroid disease compared to younger women, so this is not a fringe issue. Anyone with a known thyroid condition or unexplained symptoms of thyroid dysfunction should speak with a clinician before starting ashwagandha.
There are meaningful drug interactions that are rarely disclosed on product pages
Ashwagandha may potentiate the effects of sedatives, benzodiazepines, and other CNS depressants — a combination that is not uncommon in perimenopausal women managing anxiety or sleep disorders. It may also interact with immunosuppressants due to its observed immunomodulatory activity, and preliminary data suggest it could affect blood sugar regulation, which is relevant for women on diabetes medications. These are not theoretical concerns invented by overcautious regulators; they are documented pharmacological plausibilities that warrant a direct conversation with a prescribing doctor.
Rare but serious liver injury cases have been reported
As of 2024, a small number of case reports — including cases reviewed by the Drug-Induced Liver Injury Network — have linked ashwagandha supplementation to cholestatic liver injury, meaning bile flow was impaired. The cases were rare and most resolved after stopping the supplement, but they are documented and the mechanism is not fully understood. Women with pre-existing liver conditions or who drink alcohol regularly should be aware of this signal, and anyone developing yellowing of the skin, dark urine, or significant fatigue while taking ashwagandha should stop and seek evaluation promptly.
The evidence specifically in menopausal women is still thin
Most of the robust ashwagandha trials recruited stressed but otherwise healthy adults — not specifically perimenopausal or postmenopausal women. A small number of trials have focused on menopausal populations, including a 2021 pilot study of 100 women showing improvements in menopausal symptom scores, but sample sizes are small and follow-up periods short. It is reasonable to be cautiously optimistic, but intellectually honest to acknowledge that the evidence base for this specific population is not yet as strong as the supplement's popularity implies.
It is not a substitute for addressing the hormonal root cause of midlife stress dysregulation
The wired, anxious, overwhelmed feeling that peaks in perimenopause is substantially driven by estrogen fluctuation disrupting serotonin, GABA, and norepinephrine signaling — not simply by life being stressful. Ashwagandha addresses the downstream HPA axis response but does not touch the upstream hormonal driver. For women whose symptoms are significantly hormone-driven, using ashwagandha as a primary strategy while avoiding a conversation about HRT is a bit like putting a better fan in a room where the heating system is broken.
A reasonable trial period is 8–12 weeks at a studied dose — and knowing what to look for matters
Ashwagandha is not a supplement where effects are felt within days; the clinical trials showing meaningful cortisol and sleep improvements ran for 60 days or more, and many participants did not notice changes until weeks four to six. A fair personal trial means committing to a consistent studied dose — typically 300–600mg of a standardized extract daily — for at least eight weeks while tracking specific symptoms rather than waiting for a vague sense of feeling better. If there is no discernible change in sleep quality, perceived stress, or energy after twelve weeks, the evidence does not strongly support continuing.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.